Payments to Medical Institutions, Healthcare Professionals, etc.

Chugai discloses information in accordance with Transparency Guidelines for Chugai Activities Involving Medical Institutions, etc., to ensure the transparency of its activities with medical institutions and thereby demonstrate to the wider community that its corporate activities are based on high ethical and moral standards.
Funding provided to Japanese medical institutions and healthcare professionals for each fiscal year (January 1 to December 31) is disclosed in the following five categories:A. Research and development expenses, etc., B. Academic research support expenses, C. Manuscript/writing fees, etc., D. Information provision-related expenses, and E. other expenses.

Fiscal Year 2025

A. Research and development expenses, etc.

Research and development expenses, etc. include expenses required for research/surveillance, etc. conducted under public regulations and various policies such as the Clinical Trials Act and GCP/GVP/GPSP ordinances under the Pharmaceutical and Medical Device Act. Funds, etc. provided shall be disclosed as follows together with the annual total amount of each item.

Category Total annual transfer of value
Specified clinical trial expenses 737,670,134 (yen)
Research expenses based on ethical guidelines 934,155,692 (yen)
Research expenses other than clinical trials 1,906,587,999 (yen)
medicines 160mg
active pharmaceutical ingredients 12,004mg
antibody 4vials
active ingredients/reagents 30mg
Clinical trial expenses 3,867,481,901 (yen)
medicines 10,567,600mg
medicines 16vials
medicines 82syringes
Post-marketing clinical study expenses 141,754,696 (yen)
Adverse drug reaction/infection case reporting expenses 7,568,968 (yen)
Post-marketing surveillance expenses 67,044,386 (yen)
Other expenses 735,849,978 (yen)

B. Academic research support expenses

Scholarship donations and general donations for promotion of academic research or research support, etc., and donations to academic societies, etc. and expenses of co-sponsored conferences, etc., as expenses to academic societies, etc. for supporting conferences. Funds, etc. provided shall be disclosed as follows together with the annual total amount of each item.

Category Number of donations Total for fiscal year
Scholarship donations 971 291,500,000 (yen)
General donation 62 892,441,000 (yen)
Donation to academic society, etc. - 70,465,000 (yen)
Expenses of co-sponsored conference, etc. - 576,096,182 (yen)

C. Manuscript/writing fees, etc.

Fees, etc. for provision of scientific information, etc. on the company’s pharmaceutical products, medicine, and pharmacy or fees, etc. paid as consideration for lectures and writing or supervision of the manuscript that are related to research and development, or commissioning of services including consulting contracts, etc. Funds, etc. provided shall be disclosed as follows together with the annual total amount of each item.

Category Number of payments for fiscal year Total for fiscal year
Lecturer honoraria 13,363 959,166,517 (yen)
Manuscript writing fee/supervision fees 707 50,818,827 (yen)
Consulting, etc. commissioning fees 2,867 204,619,662 (yen)

D. Information provision-related expenses

Expenses of lecture meetings and explanation meetings, etc. for providing information, etc. related to the company’s pharmaceutical products, medicine and pharmacy to medical professionals.

Category Number of payments for fiscal year Total for fiscal year
Expenses for meetings including lectures, etc. 6,275 3,634,554,570 (yen)
Explanation meeting expenses 18,418 341,367,512 (yen)
Medical/pharmaceutical literature, etc. supply expenses - 124,014,852 (yen)

E. Other expenses

Expenses for hospitality, etc. as social courtesy

Category Total for fiscal year
Expenses for hospitality, etc. 108,385,555 (yen)

Chugai's Transparency Guidelines